In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer

Diagn Microbiol Infect Dis. 2018 Aug;91(4):351-353. doi: 10.1016/j.diagmicrobio.2018.03.009. Epub 2018 Mar 16.

Abstract

A total of 248 Gram-positive isolates from cancer patients were tested for in-vitro susceptibility to tedizolid and 3 comparator agents using CLSI broth microdilution methodology. Tedizolid inhibited 97% of isolates at ≤0.5μg/ml. It was active against all Gram-positive species and consistently had 8 fold lower MICs than linezolid, although based on % susceptibility using CLSI breakpoints, most isolates were also susceptible to the comparators. Tedizolid was active against MRSA isolates with vancomycin MICs of ≥1.0μg/ml.

Keywords: Cancer patients; Gram-positive; In-vitro; Tedizolid.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Daptomycin / pharmacology
  • Drug Resistance, Bacterial*
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Linezolid / pharmacology
  • Microbial Sensitivity Tests
  • Microbial Viability / drug effects
  • Oxazolidinones / pharmacology*
  • Tetrazoles / pharmacology*
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Oxazolidinones
  • Tetrazoles
  • Vancomycin
  • tedizolid
  • Linezolid
  • Daptomycin